 |
|
Postmarketing Surveillance and Black Box Warnings
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Lasser and colleagues1 found that 10.2% of all new drugs approved between 1975 and 1999 either acquired a black box warning or were withdrawn. Thus, they conclude that postapproval adverse drug reactions (ADRs) are common. I would like to address 2 additional issues in postmarketing surveillance.
First, premarketing clinical trials are consistently designed with a narrow spectrum of clinical disorders and participating patient profiles to achieve a required statistical result. Rarely do these patients reflect the exact clinical profiles, including use of concomitant medications, of the patient population to whom the drugs will be administered after marketing. Second, serious ADRs are often rare, albeit extremely important. Therefore, the number of patient exposures required to identify such events may be large, sometimes numbering in the millions. If only a fraction of such events is reported to either the manufacturer or the Food and Drug Administration (FDA), that . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Timing of New Black Box Warnings and Withdrawals for Prescription Medications
Karen E. Lasser, Paul D. Allen, Steffie J. Woolhandler, David U. Himmelstein, Sidney M. Wolfe, and David H. Bor
JAMA. 2002;287(17):2215-2220.
ABSTRACT
| FULL TEXT
Safety of Newly Approved Drugs: Implications for Prescribing
Robert J. Temple and Martin H. Himmel
JAMA. 2002;287(17):2273-2275.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports Project
Ladewski et al.
JCO 2003;21:3859-3866.
ABSTRACT
| FULL TEXT
|
